---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000058"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-07-22T11:10:49+00:00"
generated_at: "2026-07-22T11:15:04.976439+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Summit reports updated OS HR 0.76 for ivonescimab in HARMONi; consistent in western and Asian patients

## Summary
- Updated OS analysis from Phase III HARMONi shows HR 0.76 for full ITT population and western subgroup.
- Western patients median follow-up now 23.2 months; Asian patients locked at 32.7 months.
- Ivonescimab plus chemo continues to show acceptable safety profile; no new safety signals.
- BLA for ivonescimab in EGFR-mutated NSCLC under FDA review; PDUFA date November 14, 2026.
- Results made available to FDA; detailed data planned for presentation at upcoming medical conference.

## SEC filing metadata
- accession: 0001599298-26-000058
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-07-22T11:10:49+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/0001599298-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/smmt-20260722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000058
- JSON: https://secwatch.observer/filing/0001599298-26-000058.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.